MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Valion Bio, Inc. (VBIO)

Valion Bio, Inc. (VBIO)

|||

Cash Flow Overview

Free Cash flow
-$5,338K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Amortization of debt discount an...
    • Depreciation
    • Accrued expenses
    • Others
Negative Cash Flow Breakdown
    • Net loss from continuing operati...
    • Lease liabilities
    • Offering costs in advance of sal...
    • Others
Cash Flow
2026-06-30
2026-03-31
Net loss from continuing operations
-7,057
-6,225
Stock-based compensation
133
208
Depreciation
358
4
Amortization of debt discount and debt issuance costs
489
445
Non-cash interest expense
203
203
Change in fair value of derivative liability
47
33
Amortization of right-of-use asset
251
177
Prepaid expenses and other current assets
-163
341
Inventory
0
750
Other assets
4
86
Accounts payable
10
365
Accrued expenses
341
1,114
Lease liabilities
-114
-128
Net cash used in operating activities - continuing operations
-5,274
-5,047
Net cash provided by (used in) operating activities - discontinued operations
-7
36
Net cash used in operating activities
-5,281
-5,011
Acquisition of property and equipment
57
7
Acquisition of licensed technology
0
0
Net cash used in investing activities
-57
-7
Proceeds from issuance of common stock, net of issuance costs
69
-
Proceeds from issuance of preferred stock and common stock warrants, net of issuance costs
241
-
Proceeds from warrant exercises
-
0
Proceeds from warrant exercises, net of fees
-3
-
Offering costs in advance of sale of common stock
76
44
Net cash provided by financing activities
231
-44
Net decrease in cash and cash equivalents
-5,107
-5,062
Beginning of period
7,583
12,645
End of period
2,476
7,583
Less cash and cash equivalents included in discontinued operations
0
0
Cash and cash equivalents included in continuing operations
2,476
-
Cash and cash equivalents
2,108
-
Restricted cash
368
-
Total cash and cash equivalents included in continuing operations
2,476
7,583
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofpreferred stock and common...$241K Proceeds from issuance ofcommon stock, net of...$69K Net cash provided byfinancing activities$231K Canceled cashflow$79K Net decrease in cashand cash...-$5,107K Canceled cashflow$231K Offering costs in advanceof sale of common...$76K Proceeds from warrantexercises, net of fees-$3K Net cash used inoperating activities-$5,281K Net cash used ininvesting activities-$57K Amortization of debt discountand debt issuance...$489K Depreciation$358K Accrued expenses$341K Amortization of right-of-useasset$251K Non-cash interestexpense$203K Prepaid expenses andother current assets-$163K Stock-based compensation$133K Accounts payable$10K Net cash used inoperating activities -...-$5,274K Net cash provided by(used in) operating...-$7K Canceled cashflow$1,948K Acquisition of property andequipment$57K Net loss fromcontinuing operations-$7,057K Lease liabilities-$114K Change in fair value ofderivative liability$47K Other assets$4K